Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIR-Based Donor Selection in Haploidentical HCT
NCT02880293Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2016
- Primary completion
- Nov 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of haploidentical hematopoietic stem cells in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 6 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Proportion of Patients Undergoing an Allo HCT Transplant Who Have a KIR Favorable Donor at 1 year. Started Aug 2016; status: completed.
02
Drugs
haploidentical hematopoietic stem cells
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02880293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02880293.